Elías Campo’s team completes the genomic map of chronic lymphocytic leukemia

Elías Campo's team completes the genomic map of chronic lymphocytic leukemia

An international research team with the participation of Spanish scientists has has completed the map of genetic alterations in chronic lymphocytic leukemia (CLL).the most common in the western world with an incidence of about 5 cases per 100,000 population per year.

This tool will enable a better understanding of the disease, leading to more accurate prognosis for patients, improved diagnostics and the development of new treatments. The study, published yesterday in the journal Nature Genetics, analyzed the genomes of more than 1,000 patients.

It was coordinated by Researchers from the IDIBAPS-Hospital Clínic, the University of Barcelona, ​​​​the University of Oviedo, the Cancer Network Biomedical Research Center (Ciberonc), the Dana-Farber Cancer Institute and the Broad Institute of MIT, as well as Harvard University and the University of Ulm.

This disease is characterized by an increase in B lymphocytes, a type of white blood cell, which can be detected incidentally during routine blood tests.. In some cases it can be slow growing and have a good prognosis, while in others it can be fast and aggressive.. Knowing the molecular changes that cause this very different evolution could make it possible to know the prognosis early on.

“The aim of this study was to provide a virtually complete catalog of all genomic alterations that cause chronic lymphocytic leukemia and its molecular subtypes. It was an immense effort by a great international team has been analyzing the genomes of more than 1,000 patients with new bioinformatics tools for more than 4 years‘ noted study co-first author and head of the Molecular Pathology of Lymphoid Neoplasms Group at IDIBAPS, Elias Campo from Huesca.

The study identified 202 genes (109 of which are new) that, when mutated, can lead to the onset and progression of the disease. The characterization of the subtypes of this leukemia, which differ in their genomic properties and their clinical development, has also been perfected. Integrating clinical outcomes with such genomic traits can predict the likelihood that a patient will have very sluggish disease for many years.Remission after treatment or the possibility that your leukemia will become more aggressive and require new treatments.

The results of this study could have an important impact on clinical practice, as “the new map will allow us to compare the genomic characteristics of the new patients with data from patients with similar genetic profiles and knowing what their evolution and response to treatments was like,” he concluded.


Source link

Leave a Comment

Your email address will not be published.